Drug discovery partnerships & Research collaborations

Main partnership

FY

Category

Partners

Title

2024

Drug Discovery

PRISM BioLab

Ono Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area

2023

Drug Discovery

University of Oxford

Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford

Drug Discovery

Sibylla Biotech

Ono Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders

Drug Discovery

Harvard University

ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University

Drug Discovery

EME

Ono Enters into a Drug Discovery Collaboration Agreement with EME Aiming at the Generation of Novel VHH Antibody Drugs

Drug Discovery

InveniAI

Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

Drug Discovery

Numab

ONO Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49

Drug Discovery

Shattuck Labs

Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

Research

UK Dementia Research Institute

Ono Enters into Research Collaboration with UK Dementia Research Institute

Drug Discovery

EVQLV

Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs

Research

Turbine

Ono Enters into a Research Collaboration Agreement with Turbine to Identify and Validate Novel Therapeutic Targets in Oncology

Drug Discovery

Adimab

Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field

Drug Discovery

Twist

Ono Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases

2022

Drug Discovery

Macomics

Ono Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer

Drug Discovery

MOLCURE

Ono Enters into a Drug Discovery Collaboration Agreement with MOLCURE to Discover and Develop Innovative Antibody Drugs for Multiple Targets Utilizing MOLCURE’s AI-driven Platform Technology

Drug Discovery

PeptiDream

Ono Enters into a Drug Discovery Collaboration Agreement with PeptiDream to Discover and Develop Macrocyclic Constrained Peptide Therapeutics

Drug Discovery

Cue Biopharma

Ono Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein

Drug Discovery

KSQ Therapeutics

Ono Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics

Research

Monash University

Ono Enters an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases

Research

PrecisionLife

Ono Enters into a Multi Target R&D Collaboration Agreement with PrecisionLife

Drug Discovery

Captor Therapeutics

Ono Enters a Drug Discovery Collaboration Agreement with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases

Drug Discovery

Knowledge Palette

ONO and Knowledge Palette Enter into an Agreement to Expand Research Collaboration on Building a Data-driven New Drug Discovery Platform

Drug Discovery

Fate Therapeutics

Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Generated from the Collaboration with Fate Therapeutics

Drug Discovery

Memo Therapeutics

Ono Enters a Drug Discovery Collaboration Agreement with Memo Therapeutics to Discover and Develop Antibody Drugs in the Immuno-oncology Field

Drug Discovery

Fate Therapeutics

ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell and CAR-NK Cell Therapies for Solid Tumors

Drug Discovery

Domain Therapeutics

Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery

2021

Drug Discovery

Numab

ONO Enters into a Development and License Agreement with Numab

Drug Discovery

Iktos

ONO Enters into Collaboration Agreement with Iktos

Drug Discovery

Neurimmune

Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases

Drug Discovery

Vanderbilt University

Ono Extends Drug Discovery Collaboration Agreement with Vanderbilt University

Drug Discovery

MiraBiologics

Ono Enters into Drug Discovery Collaboration Agreement with MiraBiologics To Discover and Create Biopharmaceuticals

Research

Healx

Ono Enters into Research Collaboration Agreement with Healx Limited

Research

University of California

ONO Joins the University of California Drug Discovery Consortium

Research

PeptiDream

ONO Entered License Agreement with PeptiDream Inc. on Automated Peptide Discovery Platform System (PDPS) Platform

Research

LabCentral and MBC BioLabs

ONO Entered Sponsorship Agreements with LabCentral and MBC BioLabs

2019

Drug Discovery

Numab

ONO Enters into a New Research and Option Agreement with Numab

2018

Drug Discovery

Cancer Research UK

ONO Announces a Strategic Drug Discovery Alliance Agreement with Cancer Research UK and LifeArc for Cancer Immunotherapy

Research

Aria (twoXAR)

Ono Enters into Research Collaboration Agreement with Aria (twoXAR, Inc).

Drug Discovery

Repare Therapeutics

ONO Announces a Strategic Partnership Agreement with Repare Therapeutics for a Pol-theta Inhibitor Program

Drug Discovery

Fate Therapeutics

ONO announces collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers

2017

Drug Discovery

Merus

Ono Enters into New Collaboration Agreement with Merus N.V.

Drug Discovery

Schrödinger

ONO enters into Collaboration Agreement with Schrödinger Inc.

Drug Discovery

Cyclenium

Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc.

Drug Discovery

Neurimmune

ONO announces collaboration with Neurimmune in Neurodegenerative Diseases Field

2016

Drug Discovery

Numab

ONO Enters into a Research and Option Agreement with Numab

Drug Discovery

GHO Capital (X-Chem)

Ono Enters into Collaboration Agreement with GHO Capital (X-Chem, Inc.)

Research

Ligand

ONO Enters Into Worldwide OmniAb® Platform License Agreement With Ligand Pharmaceuticals, Inc

2014

Research

University of Tokyo

Ono Enters into the Collaboration Agreement with the University of Tokyo regarding Access to Ono’s Compound Library

2013

Research

Tohoku University, The University of Tokyo

ONO establishes an innovative research network called “Orientem Innovation” together with Tohoku University & The University of Tokyo

2012

Drug Discovery

Domain

Ono Enters into Collaboration Agreement with Domain Therapeutics in the Field of GPCR-Based Drug Discovery

Drug Discovery

BioFocus

Ono and Galapagos Subsidiary BioFocus Sign Drug Discovery Agreement in the Field of CNS Disorders

Research

BioFocus

Ono and Galapagos Subsidiary BioFocus Sign an Additional Target Discovery Agreement in the Field of Allergic Disease

Drug Discovery

Scil Proteins

Ono Enters into Drug Discovery Collaboration with Scil Proteins for Affilin® Therapeutics

2011

Drug Discovery

Receptos

Ono Enters into Drug Discovery Collaboration with Receptos on GPCR Protein Crystal Structure Determination Technology

Drug Discovery

Evotec

Lead Compounds Were Successfully Identified in Ion Channel Drug Discovery Collaboration with Evotec

2010

Research

BioFocus

Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease

2009

Drug Discovery

BioSeek

Ono Enters into Drug Discovery Agreement on Bioactive Lipid with BioSeek

Drug Discovery

Evotec

Ono Signs New Drug Discovery Agreement with Evotec AG Targeting an Ion Channel

2008

Drug Discovery

Xention

Ono Enters into Drug Discovery Agreement on Ion Channel Targets with Xention

2007

Drug Discovery

Evotec

Ono Enters into New Fragment-Based Drug Discovery Agreement on a Protease Target with Evotec AG

Research

Nissin

Ono Enters into Service Agreement with Nissin for Use of New Carcinogenicity Evaluation System, Developed by Nissin, for Pharmaceutical Compounds

Drug Discovery

Locus

Ono Enteres Into New Drug Discovery Agreement on Kinases with Locus Pharmaceuticals, Inc.

2006

Drug Discovery

Locus

Ono Entered Into Drug Discovery Agreement on Kinases with Locus Pharmaceuticals, Inc.

2005

Research

Medarex

Entered Into New Collaborative Research Agreement with Medarex for Antibody Product

Drug Discovery

Array

Ono Entered Into Drug Discovery Agreement on Kinases with Array BioPharma Inc

Research

Medarex

Ono and Medarex Enter Into Collaborative Research Agreement on Antibody Product